Magic mushrooms might treat depression? Peter Thiel-backed Compass gets FDA OK to launch Phase IIb trials
For years now, psychedelic scientists have been telling us that tripping on magic mushrooms might “reboot” the brain, clearing out negative thought networks that might contribute to depression. Now, it looks like the FDA is willing to test the theory.
Compass officially got the OK from US regulators to see how patients with depression respond to psilocybin — the active ingredient in hallucinogenic mushrooms. They’re launching a Phase IIb dose-ranging study with 216 patients. The therapy being tested includes the drug itself along with psychological support. They’ve shown promise when combined, Compass says.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.